Sep 2026· Archives of Rheumatology· 0 citations· 82 references
Medicine
TL;DR
This review article revisits the IFN-I axis in SLE and cutaneous lupus erythematosus, with special emphasis on its targeted therapies.
Abstract
For many years, systemic lupus erythematosus (SLE) pathogenesis was interpreted primarily through the lens of adaptive immunity, with emphasis on disruption of T- and B-cell tolerance, autoantibody production, immune-complex deposition, and complement activation. However, a major shift in the understanding of SLE immunopathogenesis has been the recognition that innate immune activation, and particularly the type I interferon (IFN-I) axis, provides a mechanistic link between acid sensing, antiviral-like immune activation, and tissue inflammation. While several approaches have demonstrated biological activity and provided proof-of-concept for therapeutic modulation of the IFN-I pathway, anifrolumab, a monoclonal antibody targeting IFNAR1, currently represents the most clinically validated strategy and the only approved IFN-I-targeted therapy for SLE, based on its efficacy in phase III trials. In this review article, we revisit the IFN-I axis in SLE and cutaneous lupus erythematosus, with special emphasis on its targeted therapies.
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease driven by loss of immune tolerance, dysregulated nucleic acid sensing and cytokine signaling, abnormal B- and T-cell activation, persistent autoantibody production, and impaired clearance of immune cells and debris. These interconnected abnormalit...
Yu-Rin Kim, E. Yeo, I. Kang· Current Issues in Molecular...· 0 citations
Autoimmune skin diseases (AISDs) constitute a complex group of conditions whose pathogenesis is based on abnormal activation of the immune system, leading to the production of autoantibodies and damage to skin structures. In recent years, a key role in these processes has been attributed to B lymphocytes, which not onl...
Patryk Brzezicki, Natalia Bębenek, Gabriela Barszcz et al.· International Journal of Inn...· 0 citations
Impaired interferon (IFN) production plays a key role in the pathogenesis of a wide range of autoimmune diseases (AIDs), such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), dermatomyositis, and others. This review examines both the physiological functions of IFNs under normal conditions (antiviral defe...
T. Ospelnikova, A. D. Shitova, O. N. Egorova et al.· Annals of the Russian academ...· 0 citations
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement and heterogeneous clinical manifestations. Aberrant B-cell activation and elevated levels of B-lymphocyte stimulator (BLyS) play a central role in its pathogenesis [1]. Several B-cell–targeted biologic agents hav...
Bing-Bing Deng, Zhi-Hang Xiao, Hong-Ru Wang et al.· Egyptian Rheumatology and Re...· 0 citations
Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease, and early diagnosis remains a major clinical challenge. Abnormal activation of the type I interferon (IFN) pathway is one of the core mechanisms in the pathogenesis of SLE. The IFN signature, as a biomarker reflecting activation of this pa...
Ting Chen· Explore Medical Science and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.